Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Breast Cancer

  Free Subscription


05.04.2021

1 Acta Cytol
1 Am J Surg
1 Ann Oncol
4 Ann Surg Oncol
3 Anticancer Res
4 BMC Cancer
7 Breast Cancer
1 Breast Cancer Res
5 Breast Cancer Res Treat
5 Cancer
12 Clin Breast Cancer
2 Clin Cancer Res
1 Eur J Cancer
1 Eur Radiol
1 Histopathology
1 Int J Cancer
1 Int J Radiat Oncol Biol Phys
1 J Biol Chem
4 J Clin Oncol
4 J Natl Cancer Inst
1 J Surg Oncol
1 Lancet Oncol
1 Nat Rev Clin Oncol
1 NPJ Breast Cancer
1 Oncol Rep
2 PLoS One
3 Radiol Imaging Cancer
1 Radiother Oncol


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Acta Cytol

  1. OOSTHUIZEN M, Razack R, Edge J, Schubert PT, et al
    Classification of Male Breast Lesions According to the IAC Yokohama System for Reporting Breast Cytopathology.
    Acta Cytol. 2021;65:132-139.
    PubMed         Abstract available


    Am J Surg

  2. LOVRICS O, Butt J, Lee Y, Lovrics P, et al
    The effect of bariatric surgery on breast cancer incidence and characteristics: A meta-analysis and systematic review.
    Am J Surg. 2021 Mar 18. pii: S0002-9610(21)00151.
    PubMed         Abstract available


    Ann Oncol

  3. CARIOLI G, Malvezzi M, Bertuccio P, Boffetta P, et al
    European cancer mortality predictions for the year 2021 with focus on pancreatic and female lung cancer.
    Ann Oncol. 2021 Jan 21. pii: S0923-7534(21)00014.
    PubMed         Abstract available


    Ann Surg Oncol

  4. MAGNONI F, Colleoni M, Mattar D, Corso G, et al
    Contralateral Axillary Lymph Node Metastases from Breast Carcinoma: Is it Time to Review TNM Cancer Staging?
    Ann Surg Oncol. 2020;27:4488-4499.
    PubMed         Abstract available

  5. MONTAGNA G, Mamtani A, Knezevic A, Brogi E, et al
    Selecting Node-Positive Patients for Axillary Downstaging with Neoadjuvant Chemotherapy.
    Ann Surg Oncol. 2020;27:4515-4522.
    PubMed         Abstract available

  6. TAKAHASHI H, Oshi M, Asaoka M, Yan L, et al
    Molecular Biological Features of Nottingham Histological Grade 3 Breast Cancers.
    Ann Surg Oncol. 2020;27:4475-4485.
    PubMed         Abstract available

  7. OSENI TO, Smith BL, Lehman CD, Vijapura CA, et al
    Do Eligibility Criteria for Ductal Carcinoma In Situ (DCIS) Active Surveillance Trials Identify Patients at Low Risk for Upgrade to Invasive Carcinoma?
    Ann Surg Oncol. 2020;27:4459-4465.
    PubMed         Abstract available


    Anticancer Res

  8. YAMAMOTO S, Narui K, Ishikawa T, Adachi S, et al
    First-line Gemcitabine Versus Treatment of Physician's Choice for Metastatic Breast Cancer: A Prospective Cohort Study.
    Anticancer Res. 2021;41:1671-1676.
    PubMed         Abstract available

  9. FERINI G, Molino L, Tripoli A, Valenti V, et al
    Anatomical Predictors of Dosimetric Advantages for Deep-inspiration-breath-hold 3D-conformal Radiotherapy Among Women With Left Breast Cancer.
    Anticancer Res. 2021;41:1529-1538.
    PubMed         Abstract available

  10. KRAJNAK S, Loewe A, Battista MJ, Hasenburg A, et al
    The Impact of Insulin on Low-dose Metronomic Vinorelbine and Mafosfamide in Breast Cancer Cells.
    Anticancer Res. 2021;41:1243-1250.
    PubMed         Abstract available


    BMC Cancer

  11. COLOMBIE M, Jezequel P, Rubeaux M, Frenel JS, et al
    The EPICURE study: a pilot prospective cohort study of heterogeneous and massive data integration in metastatic breast cancer patients.
    BMC Cancer. 2021;21:333.
    PubMed         Abstract available

  12. CHEN S, Han Y, Ouyang Q, Lu J, et al
    Randomized and dose-escalation trials of recombinant human serum albumin /granulocyte colony-stimulating factor in patients with breast cancer receiving anthracycline-containing chemotherapy.
    BMC Cancer. 2021;21:341.
    PubMed         Abstract available

  13. CHEN L, Dong Y, Pan Y, Zhang Y, et al
    Identification and development of an independent immune-related genes prognostic model for breast cancer.
    BMC Cancer. 2021;21:329.
    PubMed         Abstract available

  14. CHU CN, Hu KC, Wu RS, Bau DT, et al
    Radiation-irritated skin and hyperpigmentation may impact the quality of life of breast cancer patients after whole breast radiotherapy.
    BMC Cancer. 2021;21:330.
    PubMed         Abstract available


    Breast Cancer

  15. CORADINI D, Gambazza S, Oriana S, Ambrogi F, et al
    Body mass index and gamma-glutamyl transferase expression in normal and cancerous breast tissue.
    Breast Cancer. 2020;27:850-860.
    PubMed         Abstract available

  16. JAMIYAN T, Kuroda H, Yamaguchi R, Nakazato Y, et al
    Prognostic impact of a tumor-infiltrating lymphocyte subtype in triple negative cancer of the breast.
    Breast Cancer. 2020;27:880-892.
    PubMed         Abstract available

  17. IIDA M, Toyosawa D, Nakamura M, Tsuboi K, et al
    Decreased ER dependency after acquired resistance to CDK4/6 inhibitors.
    Breast Cancer. 2020;27:963-972.
    PubMed         Abstract available

  18. YAMAGUCHI M, Takagi K, Sato A, Miki Y, et al
    Rac1 activation in human breast carcinoma as a prognostic factor associated with therapeutic resistance.
    Breast Cancer. 2020;27:919-928.
    PubMed         Abstract available

  19. TOMITA M, Oura S, Nishiguchi H, Makimoto S, et al
    A case of bilateral methotrexate-associated diffuse large B-cell lymphomas of the breasts with unique clinical presentation and outcome.
    Breast Cancer. 2020;27:1038-1043.
    PubMed         Abstract available

  20. CHOI H, Noh H, Cho IJ, Lim ST, et al
    Changes in neutrophil to lymphocyte ratio (NLR) during neoadjuvant treatment correlated with patients' survival.
    Breast Cancer. 2020;27:871-879.
    PubMed         Abstract available

  21. AHMED M
    Beyond the speed of SOUND.
    Breast Cancer. 2020;27:793-795.
    PubMed         Abstract available


    Breast Cancer Res

  22. SANZ-MORENO A, Palomeras S, Pedersen K, Morancho B, et al
    RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer.
    Breast Cancer Res. 2021;23:42.
    PubMed         Abstract available


    Breast Cancer Res Treat

  23. REINHORN D, Kuchuk I, Shochat T, Nisenbaum B, et al
    Taxane versus vinorelbine in combination with trastuzumab and pertuzumab for first-line treatment of metastatic HER2-positive breast cancer: a retrospective two-center study.
    Breast Cancer Res Treat. 2021 Mar 27. pii: 10.1007/s10549-021-06198.
    PubMed         Abstract available

  24. AN KY, Arthuso FZ, Kang DW, Morielli AR, et al
    Exercise and health-related fitness predictors of chemotherapy completion in breast cancer patients: pooled analysis of two multicenter trials.
    Breast Cancer Res Treat. 2021 Mar 29. pii: 10.1007/s10549-021-06205.
    PubMed         Abstract available

  25. HELBRICH H, Braun M, Hanusch C, Mueller G, et al
    Congruence and trajectories of device-measured and self-reported physical activity during therapy for early breast cancer.
    Breast Cancer Res Treat. 2021 Mar 31. pii: 10.1007/s10549-021-06195.
    PubMed         Abstract available

  26. WANG YQ, Huang G, Chen J, Cao H, et al
    LncRNA SNHG6 promotes breast cancer progression and epithelial-mesenchymal transition via miR-543/LAMC1 axis.
    Breast Cancer Res Treat. 2021 Mar 29. pii: 10.1007/s10549-021-06190.
    PubMed         Abstract available

  27. NISHIKAWA S, Uemoto Y, Kim TS, Hisada T, et al
    Low RAI2 expression is a marker of poor prognosis in breast cancer.
    Breast Cancer Res Treat. 2021 Mar 29. pii: 10.1007/s10549-021-06176.
    PubMed         Abstract available


    Cancer

  28. SADIGH G, Gray RJ, Sparano JA, Yanez B, et al
    Breast cancer patients' insurance status and residence zip code correlate with early discontinuation of endocrine therapy: An analysis of the ECOG-ACRIN TAILORx trial.
    Cancer. 2021 Apr 1. doi: 10.1002/cncr.33527.
    PubMed         Abstract available

  29. HENDERSON V, Chukwudozie IB, Comer-Hagans D, Coffey V, et al
    Development of a culturally sensitive narrative intervention to promote genetic counseling among African American women at risk for hereditary breast cancer.
    Cancer. 2021 Apr 1. doi: 10.1002/cncr.33525.
    PubMed         Abstract available

  30. CORSO G, Maisonneuve P, Veronesi P
    Impact of radiation and hormonal therapy on the locoregional recurrence of elderly breast cancer: Are these necessary after breast-conserving surgery?
    Cancer. 2021 Apr 1. doi: 10.1002/cncr.33550.
    PubMed        

  31. TRINGALE KR, Berger ER, Heerdt AS, Braunstein LZ, et al
    Reply to Impact of radiation and hormonal therapy on the locoregional recurrence of elderly breast cancer: Are these necessary after breast-conserving surgery?
    Cancer. 2021 Apr 1. doi: 10.1002/cncr.33551.
    PubMed        

  32. CONNOR AE, Schmaltz CL, Jackson-Thompson J, Visvanathan K, et al
    Comorbidities and the risk of cardiovascular disease mortality among racially diverse patients with breast cancer.
    Cancer. 2021 Apr 1. doi: 10.1002/cncr.33530.
    PubMed         Abstract available


    Clin Breast Cancer

  33. MAHTANI R, Kittaneh M, Kalinsky K, Mamounas E, et al
    Advances in Therapeutic Approaches for Triple-Negative Breast Cancer.
    Clin Breast Cancer. 2020 Dec 29. pii: S1526-8209(20)30339.
    PubMed         Abstract available

  34. CASASANTA N, Kipnis ST, Linville L, Lipinski S, et al
    Relationship Between Hereditary Cancer Syndromes and Oncotype DX Recurrence Score.
    Clin Breast Cancer. 2020;20:125-130.
    PubMed         Abstract available

  35. SHUI R, Liang X, Li X, Liu Y, et al
    Hormone Receptor and Human Epidermal Growth Factor Receptor 2 Detection in Invasive Breast Carcinoma: A Retrospective Study of 12,467 Patients From 19 Chinese Representative Clinical Centers.
    Clin Breast Cancer. 2020;20:e65-e74.
    PubMed         Abstract available

  36. BURKE EE, Laronga C, Sun W, DeBiase S, et al
    Implant-sparing Mastectomy: An Alternative for Women Undergoing Mastectomy With Retropectoral Implants.
    Clin Breast Cancer. 2020;20:e14-e19.
    PubMed         Abstract available

  37. AYDOGAN T, Sezgin E, Ilvan S, Yilmaz OC, et al
    Comparison of Radio-guided Occult Lesion Localization (ROLL) and Magnetic Occult Lesion Localization (MOLL) for Non-palpable Lesions: A Phantom Model Study.
    Clin Breast Cancer. 2020;20:e9-e13.
    PubMed         Abstract available

  38. CUTULI B, Lemanski C, De Lafontan B, Chauvet MP, et al
    Ductal Carcinoma in Situ: A French National Survey. Analysis of 2125 Patients.
    Clin Breast Cancer. 2020;20:e164-e172.
    PubMed         Abstract available

  39. TU CW, Fang CL, Tsai CB, Hsu CH, et al
    Breast Reconstruction After Resection of Bilateral Giant Phyllodes Tumors: Two Separate Deep Inferior Epigastric Perforator Flaps From One Donor Site.
    Clin Breast Cancer. 2020;20:e188-e191.
    PubMed        

  40. FOUNTZILAS E, Konstantopoulou I, Vagena A, Apostolou P, et al
    Pathology of BRCA1- and BRCA2-associated Breast Cancers: Known and Less Known Connections.
    Clin Breast Cancer. 2020;20:152-159.
    PubMed         Abstract available

  41. GUILLAUME Z, Medioni J, Lillo-Lelouet A, Marret G, et al
    Severe Cellular Immunodeficiency Triggered by the CDK4/6 Inhibitor Palbociclib.
    Clin Breast Cancer. 2020;20:e192-e195.
    PubMed        

  42. MCEVOY MP, Ravetch E, Patel G, Fox J, et al
    Prevention of Breast Cancer-Related Lymphedema.
    Clin Breast Cancer. 2021 Mar 17. pii: S1526-8209(21)00051.
    PubMed         Abstract available

  43. FUSHIMI A, Kudo R, Takeyama H
    Do Decreased Breast Microcalcifications After Neoadjuvant Chemotherapy Predict Pathologic Complete Response?
    Clin Breast Cancer. 2020;20:e82-e88.
    PubMed         Abstract available

  44. ROBERTSON SJ, Pond GR, Hilton J, Petkiewicz SL, et al
    Selecting Patients for Oncotype DX Testing Using Standard Clinicopathologic Information.
    Clin Breast Cancer. 2020;20:61-67.
    PubMed         Abstract available


    Clin Cancer Res

  45. VERNIERI C, Nichetti F, Lalli L, Moscetti L, et al
    Impact of baseline and on-treatment glycemia on everolimus-exemestane efficacy in patients with hormone receptor-positive advanced breast cancer (EVERMET).
    Clin Cancer Res. 2021 Mar 30. pii: 1078-0432.CCR-20-4928.
    PubMed         Abstract available

  46. AKCAKANAT A, Zheng X, Cruz Pico CX, Kim T, et al
    Genomic, Transcriptomic and Proteomic Profiling of Metastatic Breast Cancer.
    Clin Cancer Res. 2021 Mar 29. pii: 1078-0432.CCR-20-4048.
    PubMed         Abstract available


    Eur J Cancer

  47. PEREZ-GARCIA JM, Llombart-Cussac A, G Cortes M, Curigliano G, et al
    Pembrolizumab plus eribulin in hormone-receptor-positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase trial.
    Eur J Cancer. 2021;148:382-394.
    PubMed         Abstract available


    Eur Radiol

  48. CHOI WJ, Kim SH, Shin HJ, Bang M, et al
    Automated breast US as the primary screening test for breast cancer among East Asian women aged 40-49 years: a multicenter prospective study.
    Eur Radiol. 2021 Mar 29. pii: 10.1007/s00330-021-07864.
    PubMed         Abstract available


    Histopathology

  49. WILLIAMS B, Hanby A, Millican-Slater R, Verghese E, et al
    Digital pathology for primary diagnosis of screen-detected breast lesions - experimental data, validation and experience from four centres.
    Histopathology. 2020;76:968-975.
    PubMed         Abstract available


    Int J Cancer

  50. PARK YM, Shivappa N, Petimar J, Hodgson ME, et al
    Dietary inflammatory potential, oxidative balance score, and risk of breast cancer: findings from the Sister Study.
    Int J Cancer. 2021 Mar 30. doi: 10.1002/ijc.33581.
    PubMed         Abstract available


    Int J Radiat Oncol Biol Phys

  51. LING DC, Vargo JA, Beriwal S
    Breast, Prostate, and Rectal Cancer: Should 5-5-5 Be a New Standard of Care?
    Int J Radiat Oncol Biol Phys. 2020;108:390-393.
    PubMed        


    J Biol Chem

  52. LANDOR SKJ, Santio NM, Eccleshall WB, Paramonov VM, et al
    PIM-induced phosphorylation of Notch3 promotes breast cancer tumorigenicity in a CSL-independent fashion.
    J Biol Chem. 2021 Mar 25:100593. doi: 10.1016/j.jbc.2021.100593.
    PubMed         Abstract available


    J Clin Oncol

  53. CIRUELOS EM, Rugo HS, Mayer IA, Levy C, et al
    Patient-Reported Outcomes in Patients With PIK3CA-Mutated Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer From SOLAR-1.
    J Clin Oncol. 2021 Mar 29:JCO2001139. doi: 10.1200/JCO.20.01139.
    PubMed         Abstract available

  54. FASCHING PA, Yadav S, Hu C, Wunderle M, et al
    Mutations in BRCA1/2 and Other Panel Genes in Patients With Metastatic Breast Cancer -Association With Patient and Disease Characteristics and Effect on Prognosis.
    J Clin Oncol. 2021 Mar 29:JCO2001200. doi: 10.1200/JCO.20.01200.
    PubMed         Abstract available

  55. ANDO K, Shimomura A, Yoshimura K, Kawamura Y, et al
    What Is the Optimal Model to Estimate the Benefits of Chemotherapy in Patients With Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer?
    J Clin Oncol. 2021 Apr 1:JCO2100178. doi: 10.1200/JCO.21.00178.
    PubMed        

  56. LOIBL S, Marme F, Martin M, Untch M, et al
    Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial.
    J Clin Oncol. 2021 Apr 1:JCO2003639. doi: 10.1200/JCO.20.03639.
    PubMed         Abstract available


    J Natl Cancer Inst

  57. PISANO ED, Gatsonis C, Sparano J, Troester MA, et al
    RE: Advanced Breast Cancer Definitions by Staging System Examined in the Breast Cancer Surveillance Consortium.
    J Natl Cancer Inst. 2021 Mar 30. pii: 6203812. doi: 10.1093.
    PubMed        

  58. POLLEY MC
    On the Quest of Risk Stratification in HER2-Positive Breast Cancer.
    J Natl Cancer Inst. 2021 Mar 31. pii: 6206391. doi: 10.1093.
    PubMed        

  59. CHIC N, Luen SJ, Nuciforo P, Salgado R, et al
    Tumor Cellularity and Infiltrating Lymphocytes (CelTIL) as a Survival Surrogate in HER2-Positive Breast Cancer.
    J Natl Cancer Inst. 2021 Mar 31. pii: 6206389. doi: 10.1093.
    PubMed         Abstract available

  60. REINER AS, Watt GP, John EM, Lynch CF, et al
    Smoking, Radiation Therapy, and Contralateral Breast Cancer Risk in Young Women.
    J Natl Cancer Inst. 2021 Mar 29. pii: 6199433. doi: 10.1093.
    PubMed         Abstract available


    J Surg Oncol

  61. LYNCH KT, Kane WJ, Fleming MA, Desai RP, et al
    Childhood cancer survivors face markedly worse overall survival after diagnosis with breast cancer, melanoma, or colorectal cancer.
    J Surg Oncol. 2021 Mar 31. doi: 10.1002/jso.26478.
    PubMed         Abstract available


    Lancet Oncol

  62. RUGO HS, Lerebours F, Ciruelos E, Drullinsky P, et al
    Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study.
    Lancet Oncol. 2021;22:489-498.
    PubMed         Abstract available


    Nat Rev Clin Oncol

  63. PALUCH-SHIMON S, Cardoso F
    PARP inhibitors coming of age.
    Nat Rev Clin Oncol. 2021;18:69-70.
    PubMed        


    NPJ Breast Cancer

  64. YANG X, Cai GX, Han BW, Guo ZW, et al
    Association between the nucleosome footprint of plasma DNA and neoadjuvant chemotherapy response for breast cancer.
    NPJ Breast Cancer. 2021;7:35.
    PubMed         Abstract available


    Oncol Rep

  65. TOUMAZI D, El Daccache S, Constantinou C
    An unexpected link: The role of mammary and gut microbiota on breast cancer development and management (Review).
    Oncol Rep. 2021;45.
    PubMed         Abstract available


    PLoS One

  66. KOOP Y, Dobbe L, Maas AHEM, van Spronsen DJ, et al
    Oncology professionals' perspectives towards cardiac surveillance in breast cancer patients with high cardiotoxicity risk: A qualitative study.
    PLoS One. 2021;16:e0249067.
    PubMed         Abstract available

  67. GONG Z, Chen J, Wang J, Liu S, et al
    Differential methylation and expression patterns of microRNAs in relation to breast cancer subtypes among American women of African and European ancestry.
    PLoS One. 2021;16:e0249229.
    PubMed         Abstract available


    Radiol Imaging Cancer

  68. LUKER GD
    MRI Screening Reduces Interval Breast Cancer in Women with Dense Breasts.
    Radiol Imaging Cancer. 2020;2:e204002.
    PubMed        

  69. KOMOROSKI RA, Lee JH, Welge JA, Dudley JA, et al
    (1)H MR Spectroscopy of Fine-Needle Aspiration Biopsy Specimens for the Discrimination of Breast Cancer.
    Radiol Imaging Cancer. 2020;2:e200033.
    PubMed         Abstract available

  70. MILES RC
    Closing the Gap: Disparities in Breast Cancer Mortality among African American Women.
    Radiol Imaging Cancer. 2020;2:e200124.
    PubMed        


    Radiother Oncol

  71. BEHROOZIAN T, Milton L, Zhang L, Lou J, et al
    How do patient-reported outcomes compare with clinician assessments? A prospective study of radiation dermatitis in breast cancer.
    Radiother Oncol. 2021 Mar 23. pii: S0167-8140(21)06146.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: